Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The user's experience taking Pyrilutamide, a drug for hair loss treatment, and their use of it in combination with other treatments such as Minoxidil, Finasteride and RU58841. They have experienced positive results so far with no major side effects.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

A person with Alopecia Areata on their beard is using CB-03-01 and oral minoxidil for treatment. Some users question the effectiveness of CB-03-01 for beard hair, suggesting that minoxidil alone may be responsible for any observed hair growth.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.

Tretinoin combined with minoxidil is effective for hair loss and can be used once daily. The user seeks a compounding pharmacy to mix these without finasteride.

The conversation is about treating hair loss without finasteride or dutasteride due to sensitivity causing gynecomastia. The user plans to use pyrilutamide, RU58841, and oral Minoxidil instead.

User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.

The user is exploring alternatives to finasteride and dutasteride due to concerns about side effects, and is using rosemary and jojoba oil, ketoconazole, minoxidil, microneedling, multi-peptide serum, saw palmetto, and stinging nettle for hair loss. They are also considering CB 03 01 and spironolactone.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation is about using vitamin C and Magnesium L-Threonate for hair growth by reducing DHT binding to dermal papilla cells. The original post about vitamin C's pH levels and sebum control was possibly removed by a moderator.

The conversation humorously discusses various unconventional and satirical hair loss treatments, including Minoxidil, RU58841, dutasteride, and microneedling. It also mentions bizarre suggestions like topical sharpie, spray paint, and Nutella.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.